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For a global understanding of the physiological impact of the nuclear hormone
1α,25-dihydroxyvitamin D3 (1,25(OH)2D3) the analysis of the genome-wide locations
of its high affinity receptor, the transcription factor vitamin D receptor (VDR), is
essential. Chromatin immunoprecipitation sequencing (ChIP-seq) in GM10855 and
GM10861 lymphoblastoid cells, undifferentiated and lipopolysaccharide-differentiated
THP-1 monocytes, LS180 colorectal cancer cells and LX2 hepatic stellate cells revealed
between 1000 and 13,000VDR-specific genomic binding sites. The harmonized analysis
of these ChIP-seq datasets indicates that the mechanistic basis for the action of the VDR
is independent of the cell type. Formaldehyde-assisted isolation of regulatory elements
sequencing (FAIRE-seq) data highlight accessible chromatin regions, which are under
control of 1,25(OH)2D3. In addition, public data, such as from the ENCODE project,
allow to relate the genome-wide actions of VDR and 1,25(OH)2D3 to those of other
proteins within the nucleus. For example, locations of the insulator protein CTCF suggest
a segregation of the human genome into chromatin domains, of which more than 1000
contain at least one VDR binding site. The integration of all these genome-wide data
facilitates the identification of the most important VDR binding sites and associated
primary 1,25(OH)2D3 target genes. Expression changes of these key genes can serve
as biomarkers for the actions of vitamin D3 and its metabolites in different tissues and
cell types of human individuals. Analysis of primary tissues obtained from vitamin D3
intervention studies using such markers indicated a large inter-individual variation for the
efficiency of vitamin D3 supplementation. In conclusion, a genome-wide (over)view on
the genomic locations of VDR provides a broader basis for addressing vitamin D’s role in
health and disease.
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INTRODUCTION
During evolution the secosteroid vitaminD3 became a pleiotropic
signaling molecule (Jones et al., 1998). Initially, the molecule
was used by early unicellular organisms to protect their DNA
against UV-B irradiation (Holick, 2011). Far later, when the first
fish with bones evolved, the endocrinology of vitamin D3 was
established, and still is very conserved in all higher organisms,
including humans (Bouillon and Suda, 2014). In this system,
the energy of UV-B is used to convert 7-dehydrocholesterol into
Abbreviations: 1,25(OH)2D3, 1α,25-dihydroxyvitamin D3; 25(OH)D3, 25-
hydroxyvitamin D3; ALOX5, arachidonate 5-lipoxygenase; CBS, cystathionine
β-synthase; CCNC, cyclin C; CDKN1A, cyclin-dependent kinase inhibitor 1A;
CHD7, chromodomain helicase DNA binding protein 7; ChIA-PET, chro-
matin interaction analysis by paired-end tag sequencing; ChIP, chromatin
immunoprecipitation; ChIP-seq, ChIP coupled with massive parallel sequencing;
CTCF, CCCTC-binding factor; CYP, cytochrome P450; DNase-seq, DNase I
hypersensitivity sites sequencing; DR3, direct repeat spaced by 3 nucleotides;
FAIRE-seq, formaldehyde-assisted isolation of regulatory elements sequencing;
IGV, Integrative Genomics Viewer; LPS, lipopolysaccharide; LRP5, low density
lipoprotein receptor-related protein 5; MYC, v-myc avian myelocytomatosis viral
oncogene homolog; PBMC, peripheral blood mononuclear cell; RXR, retinoid
X receptor; THBD, thrombomodulin; TNFSF11, tumor necrosis factor (ligand)
superfamily, member 11; TRPV6, transient receptor potential cation channel,
subfamily V, member 6; TSS, transcription start site; VDR, vitamin D receptor;
ZMIZ1, zinc finger, MIZ-type containing 1.
pre-vitamin D3, i.e., UV-B became essential for the synthesis
of vitamin D3 (Holick, 2004) (more details in the article by
Reichrath et al. in this issue). The central importance of this
step is emphasized by the step-wise depigmentation of human
skin, when modern humans started to move out of Africa some
100,000 years ago (Hochberg and Templeton, 2010). Two hydrox-
ylation steps are necessary for the conversion of vitamin D3 via
25-hydroxyvitamin D3 (25(OH)D3) into the biologically active
vitamin D3 metabolite, 1,25(OH)2D3 (Norman, 2008). The latter
molecule participates in a large number of physiological pro-
cesses, such as bone formation, immune function and cellular
growth and differentiation (Deluca, 2004) (more details in the
articles by van Leeuwen et al., Hewison et al. and Munoz et al.
in this issue).
The transcription factor VDR is the only high-affinity tar-
get for 1,25(OH)2D3 within the cell nucleus (Haussler et al.,
1997). VDR is one of approximately 1900 transcription factors,
which are encoded by the human genome (Vaquerizas et al.,
2009). In addition, VDR is a member of the superfamily of
nuclear receptors, most of which are specifically activated by
lipophilic molecules in the size of cholesterol (Carlberg and
Molnár, 2012). Its lipophilic allows 1,25(OH)2D3 to pass through
all biological membranes, i.e., gene regulation by vitamin D
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does not involve additional signal transduction steps, as they
are known for hydrophilic signaling molecules, such as peptide
hormones, growth factors and cytokines.Moreover, VDR is rather
ubiquitously expressed, i.e., most human tissues and cell types are
responsive to 1,25(OH)2D3 (Wang et al., 2012).
VDR shares the main structural characteristics of nuclear
receptors, which is a highly conserved DNA-binding domain and
a structurally conserved ligand-binding domain (Mangelsdorf
et al., 1995). VDR’s DNA-binding domain specifically contacts the
hexameric consensus sequence RGKTSA (R = A or G, K = G
or T, S = C or G) within the major groove of genomic DNA
(Shaffer and Gewirth, 2002). However, like most other transcrip-
tion factors, VDR uses a partner DNA-binding protein, in order
to bind efficiently to its target sites. More than 20 years ago,
this heterodimeric partner turned out to be the nuclear recep-
tor retinoid X receptor (RXR) (Sone et al., 1991; Carlberg et al.,
1993). Steric constraints of the dimerizing DNA-binding domains
of VDR and RXR determine the optimal binding site of the VDR-
RXR complex as a direct repeat of two hexameric nuclear receptor
binding motifs spaced by three nucleotides (DR3) (Umesono
et al., 1991; Shaffer and Gewirth, 2004). Within VDR’s ligand-
binding domain, a network of some 40 mostly non-polar amino
acids forms a ligand-binding pocket, in which 1,25(OH)2D3
and its synthetic analogs are specifically fixed with high affin-
ity (Molnár et al., 2006). This ligand binding process induces a
conformational change to the surface of VDR’s ligand-binding
domain, which results in a significant change of VDR’s protein-
protein interaction profile: it transforms from a repressor to an
activator (Moras and Gronemeyer, 1998; Carlberg and Campbell,
2013) (more details on VDR structure in the article by Molnar in
this issue).
Taken together, vitamin D signaling primarily comprises the
molecular actions of the VDR, i.e., the physiological effects
of 1,25(OH)2D3 are largely identical to those of its recep-
tor. This reduces vitamin D signaling to one central ques-
tion: which are the most important genomic targets of VDR
in a given tissue and which genes are controlled via these
sites? Thus, this review focuses on the description of the
genome-wide binding of VDR and its mechanistic implica-
tions. This analysis will be in the context of genome-wide
information on chromatin accessibility and the presence of
other nuclear proteins, such as provided by the ENCODE
consortium.
GENOME-WIDE VDR BINDING
The method chromatin immunoprecipitation (ChIP) was devel-
oped, in order to monitor the binding of transcription factors to
their genomic targets (Orlando, 2000). The core of the method is
(i) mild chemical cross-linking of living cells or tissues, e.g., with
1% formaldehyde, in order to fix nuclear proteins to genomic
DNA, (ii) sonication of chromatin into small (200–400 bp) frag-
ments, and (iii) immunoprecipitation with an antibody specific
for the chosen nuclear protein (Maston et al., 2012). In this
way, chromatin regions, which, at the moment of cross-linking,
had been in contact with the protein of choice, are specifically
enriched. A specific ChIP signal, in reference to a control (often
unspecific IgGs), is a strong indication that the protein of choice
had been in contact with the selected genomic region at the
moment of cross-linking.
At earlier times, the isolated chromatin template was analyzed
by site-specific quantitative PCR (ChIP-qPCR). This approach
had been used to study, for example, the extended promoter
regions of the primary VDR target genes CYP24A1 (Väisänen
et al., 2005), CYP27B1 (Turunen et al., 2007), CCNC (Sinkkonen
et al., 2005), and CDKN1A (Saramäki et al., 2006, 2009).
Alternatively, the abundance of immunoprecipitated chromatin
fragments had been detected by tiled microarrays (so-called
“chips,”) which covered a selection of promoter and enhancer
regions or any other subset of the genome (ChIP-chip). The group
of Pike et al. had extensively used ChIP-chip, in order to locate
VDR binding sites within the regulatory regions of the mouse
genes Vdr (Zella et al., 2006), Trpv6 (Meyer et al., 2006), Lrp5
(Fretz et al., 2007), Tnfsf11 (also known as Rankl) (Kim et al.,
2006), Cyp24a1 (Meyer et al., 2010), and Cbs (Kriebitzsch et al.,
2011). The latest development of the ChIP method is the unbi-
ased analysis of the precipitated chromatin by massively parallel
DNA sequencing (ChIP-seq), i.e., the detection of the binding
sites of the transcription factor of choice in the complete genome.
To date, ChIP-qPCR is primarily used for the confirmation of
ChIP-seq results, while ChIP-chip got outdated shortly after its
introduction. This leaves, at present, ChIP-seq as the method of
choice for analyzing VDR’s genomic binding loci.
At present, the readouts of massive parallel sequencing are
small sequence tags (35–50 nucleotides), but in the future there
will be in majority longer reads used, which will lead to improved
significance of the results. These sequence tags are aligned to a ref-
erence genome (for human samples this is, at present, hg19) and
specifically represent the enriched chromatin fragments. Then
“peak calling” software is used to identify genomic regions, in
which significantly more sequence tags are detected than in con-
trol reactions. Therefore, tags that accumulate as “peaks” at spe-
cific genomic loci mark the presence of the investigated nuclear
protein (Park, 2009; Furey, 2012). At present, ChIP is still per-
formed with millions of cells; in case of a prominent binding site,
most of these cells contribute to the ChIP signal, i.e., it can be
assumed that in the majority of cells the locus is occupied by
VDR. However, when only in some cells a site is bound by VDR,
the respective peak is far less prominent, i.e., most likely of less
impact for the regulation of 1,25(OH)2D3 target genes.
To date, VDR ChIP-seq data are available from (i) the
immortalized lymphoblastoid cell lines GM10855 and GM10861
(Ramagopalan et al., 2010), (ii) undifferentiated THP-1
monocyte-like cells (Heikkinen et al., 2011), (iii) lipopolysaccha-
ride (LPS)-polarized THP-1 macrophage-like cells (Tuoresmäki
et al., 2014), (iv) LS180 colorectal cancer cells (Meyer et al.,
2012), and (v) LX2 hepatic stellate cells (Ding et al., 2013). The
original publications reported between 1600 and 6200VDR
binding sites (in ligand-stimulated samples) within the human
genome. However, these numbers are not directly comparable,
since different peak calling software, alternative threshold settings
and even an older version of the reference genome (hg18) were
used. A harmonized re-analysis of all six VDR ChIP-seq datasets
with identical peak calling settings (MACS, version 2) resulted
for 1,25(OH)2D3-stimulated and unstimulated cells, respectively,
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in following number of binding sites: 6172 and 3144 (GM10855),
12,353 and 4072 (GM10861), 774 and 609 (undifferentiated
THP-1), 953 and 529 (LPS-differentiated THP-1), 3777 and 165
(LS180) and 1532 and 1474 (LX2) (Tuoresmäki et al., 2014).
In total, the six VDR ChIP-seq datasets indicated 21,776 non-
overlapping VDR binding sites when allowing a distance of up
to 250 bp between the peak summits (Tuoresmäki et al., 2014).
However, the vast majority of these VDR loci (67%) are unique
for one of the analyzed cellular models. In contrast, under the
above mentioned conditions only 54 sites are common within all
six datasets. In general, this indicates that VDR displays a very
individual pattern of cell-specific genomic locations, which over-
laps between multiple tissues only at key sites. The VDR binding
site of the 1,25(OH)2D3 target gene ZMIZ1, which is located
15.3 kb downstream of the transcription start site (TSS), repre-
sents an example of such a locus (Figure 1). In general, the rates
of overlaps between the cell types follow roughly their develop-
mental and functional relatedness, i.e., the two lymphoblastoid
cell lines, GM10855 and GM10861, or LPS-differentiated and
undifferentiated THP-1 cells show more overlapping VDR bind-
ing sites than all other comparisons between the VDR ChIP-seq
datasets.Moreover, the VDR binding profiles of ligand-stimulated
cells matched better than those of unstimulated cells (Tuoresmäki
et al., 2014).
Genome-wide studies on VDR binding have changed the view
on vitamin D signaling. The few dozens rather well character-
ized VDR binding sites in less than 10 kb distance to the TSS
of 1,25(OH)2D3 target genes (Haussler et al., 2013), which were
known before, were complemented by thousands of additional
VDR loci spread over the whole genome. However, the very most
of the loci, which were highlighted by ChIP-seq, have not yet
been validated by ChIP-qPCR or similar methods (and many
will never be confirmed). Some previously known VDR bind-
ing sites, such as those controlling the genes MYC (Toropainen
et al., 2010), VDR (Zella et al., 2010), CCNC (Sinkkonen et al.,
2005), and ALOX5 (Seuter et al., 2007), could be confirmed by the
VDR ChIP-seq datasets. However, for many known 1,25(OH)2D3
target genes the ChIP-seq data suggest additional or alternative
VDR binding sites, many of these being far more distant to the
gene’s TSS region than previously foreseen. In the past, many of
these VDR binding sites had been overlooked due to a focus to
only a few kb upstream of the TSS of 1,25(OH)2D3 target genes.
However, in accordance with the results of the ENCODE project
(ENCODE-Project-Consortium et al., 2012), VDR binding sites
are found with equal probability upstream and downstream of
the TSS region of 1,25(OH)2D3 target genes. In addition, VDR
loci in distance of even more than 1 Mb from the gene’s TSS are
accepted as regulatory sites (more details below).
In summary, there seem to be 1000–10,000 genomic VDR
binding sites per cell type. This is farmore than the number of pri-
mary 1,25(OH)2D3 target genes, which is in the order of 100-500
per tissue. This even holds true for undifferentiated THP-1 cells,
where 774VDR loci in ligand-stimulated cells are facing 408 sta-
tistically significantly up-regulated early 1,25(OH)2D3 respond-
ing genes (Heikkinen et al., 2011). The indicates that some genes
are controlled by more than one VDR binding site, i.e., they may
have a higher potential to be regulated by 1,25(OH)2D3 than
target genes with only one active VDR locus (more details on
the transcriptome-wide response to 1,25(OH)2D3 in the article
by Campbell et al. in this issue).
MECHANISTIC INSIGHT FROM VDR ChIP-SEQ STUDIES
The close to 22,000 non-overlapping VDR peaks, which are indi-
cated by the public ChIP-seq datasets (Tuoresmäki et al., 2014),
show rather different characteristics. Despite the rather different
total number of reported VDR peaks per cellular model, each of
the six ChIP-seq datasets contains an in part overlapping sub-
set of less than 200 sites, where a stimulation with 1,25(OH)2D3
resulted in a significant increase of VDR binding compared to
unstimulated samples. These VDR loci are far more prominent
than most of the other sites, for which ligand treatment was either
repressive, had no effect or was only minor stimulatory.
Another important parameter for the characterization of a
VDR binding site is the presence or absence of a high confi-
dence DR3-type binding site below the summit (±100 bp) of
the respective ChIP-seq peak. This can be investigated with the
help of binding site screening algorithms, such as provided by
HOMER (Heinz et al., 2010). Depending on the threshold set-
tings the software detects binding sites that deviate more or less
from the consensus sequence. For example, for a moderate setting
of a HOMER score of 7, from the total of 21,776 non-overlapping
VDR sites in all six ChIP-seq datasets only 3801 (17.5%) contain
a DR3-type sequence. Interestingly, the percentage of DR3-type
motifs differs significantly between the datasets and ranges from
38.2% (483 of 1264 sites) in LPS-polarized THP-1 cells via 36.4%
(373 of 1023) in undifferentiated THP-1 cells, 28.6% (1062 of
3706) in LS180 cells, 27.8% (611 of 2194) in LX2 cells, 13.0% (909
of 6975) in GM10855 cells to 9.0% (1118 of 12,438) in GM10861
cells. This indicates that the total number of identified VDR bind-
ing sites in each cell line inversely correlates with the percentage
of peak summits with DR3-type sites. However, when the analysis
is restricted to the top 200VDR sites (based on fold enrichment
scoring), for all six ChIP-seq datasets a DR3-like sequence rate
of more than 60% is observed, i.e., DR3 motifs are found pref-
erentially at highly ligand responsive VDR loci. In this way, the
different VDR ChIP-seq datasets show a very similar relationship
between VDR occupancy and DR3 percentage. This suggests that
the mechanistic basis for the action of the VDR is independent of
the cell type and the total number of identified binding sites.
Transcription factor binding site screening software, such as
HOMER, suggests that DR3-type binding sequences are the most
abundant sites below the summits of VDR ChIP-seq peaks.
However, a significant number of the genomic VDR loci (depend-
ing on the dataset 60-90% of all, see above) do not associate
with a DR3-type site. This indicates that at these loci VDR uses
a different mode of interaction with genomic DNA. This could
be either the use of a different heterodimeric binding partner
or an indirect binding “backpack” of a DNA-binding transcrip-
tion factor (Carlberg and Campbell, 2013). In both scenarios
the specific DNA binding site would be different to a DR3-type
sequence. Interestingly, for the VDR ChIP-seq datasets originat-
ing from hematopoietic cells, HOMER indicated binding sites for
the transcription factors PU.1 (also called SPI1), ESRRB (also
called NR3B2) and GABPA as significantly enriched (Tuoresmäki
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FIGURE 1 | Conserved genomic VDR binding in six cellular models.
The Integrative Genomics Viewer (IGV) browser (Robinson et al.,
2011) was used to visualize the VDR binding site 15.3 kb
downstream of the ZMIZ1 TSS. The peak tracks display data from
VDR ChIP-seq datasets from two B cell-like cells (dark and light
blue), monocyte-like cells (red), macrophage-like cells (orange), colon
cells (gray) and liver cells (violet). The cells were either unstimulated
(−) or treated with VDR ligand (+). The gene structures are shown
in blue and the sequence of the DR3-type element below the
summit of the VDR peak is indicated.
et al., 2014). PU.1 is well-known as a pioneer factor (Zaret and
Carroll, 2011), i.e., as a transcription factor with (i) a high num-
ber of genomic binding sites, (ii) a greater binding promiscuity
and (iii) higher diversity of interactions. Pioneer factors are the
first that bind regulatory genomic regions, such as promoters and
enhancers, and interact with chromatin modifying enzymes, in
order make the chromatin more accessible for regular transcrip-
tion factors, such as VDR. At present, a direct protein-protein
interaction of VDR with PU.1, ESRRB or GABPA has not been
demonstrated, but for the Ets family, to which PU.1 belongs, there
were indications for an interaction (Tolon et al., 2000). However,
for the pure function as a pioneer factor a direct protein-protein
interaction with the “settler factor” is not needed.Moreover, there
is older evidence from single gene studies that DNA binding of
VDR is modulated by the transcription factors AP1 (Schüle et al.,
1990) and RUNX2 (Sierra et al., 2003). In contrast, a genome-
wide study on the interaction of VDR with the transcription
factor TCF7L2 did not provide any evidence that the latter acts
as a pioneer factor for VDR (Meyer et al., 2012).
Below VDR peak summits no dominant non-DR3 binding
sequence could be identified. Moreover, the six VDR ChIP-seq
datasets differ in the ranking and identity of the non-DR3 sites
found below the peaks (Tuoresmäki et al., 2014). This suggests
that in total there must be a larger number of VDR partnering
proteins. Most likely, these proteins have a cell-specific expression
pattern and may explain in part the cell-specific actions of VDR
and its natural ligand 1,25(OH)2D3. Moreover, ChIP-seq datasets
have indicated that, in contrast to steroid receptors, VDR binds
a number of its genomic targets already in the absence of lig-
and. These ligand-independent genomic VDR loci have a clearly
lower rate of DR3-type sequences than ligand-dependent sites
(Heikkinen et al., 2011). In contrast, they associate preferentially
with proteins related to gene repression, such as demonstrated for
the example of the CYP27B1 gene (Turunen et al., 2007). This
implies that the functional profile of VDR is larger than that of
its ligand (Polly et al., 2000) as previously shown for other mem-
bers of the nuclear receptor superfamily, such as thyroid hormone
receptor or liver X receptor (Perissi et al., 2010).
Taken together, all VDR ChIP-seq studies confirm the pref-
erential binding of VDR to DR3-type sequences. However, only
one in six of some 22,000 presently known VDR loci within the
human genome carry a DR3 site. Thus, there have to be addi-
tional mechanisms for the association of VDR with its genomic
loci, which may include partnering with presently undefined
partner proteins or the tethering to other DNA-binding tran-
scription factors, such as pioneer factors. These should explain
some of the cell-specific actions as well as repressive functions of
1,25(OH)2D3 and the VDR.
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RESPONSES OF CHROMATIN TO 1,25(OH)2D3
Histone proteins forming the nucleosome core are DNA-
binding proteins but do not show any sequence specificity.
Therefore, the complex of nucleosomes and genomic DNA,
which is referred to as chromatin, has an intrinsic repres-
sive potential: it prevents access of transcription factors to
their genomic targets (Razin, 1998). This provides essential sta-
bility to the epigenetic landscape for long-lasting regulatory
decisions, such as gene expression in terminally differentiated
cells (Mohn and Schubeler, 2009). In contrast, some regions
of the epigenome show highly dynamic changes in response
to extra- and intracellular signals, such as the activation of
VDR by 1,25(OH)2D3 binding (Talbert and Henikoff, 2006).
These changes involve the methylation of genomic DNA and/or
reversible post-translational modifications of histone proteins,
such as acetylation or deacetylation at exposed lysine residues
(Narlikar et al., 2002). Dynamic chromatin modifications change
the access to regulatory genomic regions, such as promoter
and enhancers, for the binding of transcription factors, i.e.,
they determine whether at these regions chromatin is open or
closed. This can be monitored genome-wide by using the method
DNase I hypersensitive sites sequencing (DNase-seq), which high-
lights genomic regions being most sensitive to cleavage by the
enzyme DNase I (Crawford et al., 2006). A very similar tech-
nique is Formaldehyde-Assisted Isolation of Regulatory Elements
sequencing (FAIRE-seq), which identifies genome-wide accessi-
ble DNA regions (Giresi et al., 2007) (more details on the relation
of the epigenome and 1,25(OH)2D3 in the article by Kallay et al.
in this issue).
At present, the only publically available dataset describing
genome-wide effects of 1,25(OH)2D3 on the epigenome, is a
detailed FAIRE-seq time course in THP-1 cells (Seuter et al.,
2013). These data demonstrate that some 87% of the more than
1000VDR binding sites in this cellular model co-localize with
open chromatin. Interestingly, at 165 of these VDR loci a strong
1,25(OH)2D3-dependent increase of chromatin accessibility is
found. Importantly, at 66% of these chromatin regions a DR3-
type sequence is found, i.e., they overlap with loci, at which VDR
binding is enhanced most by 1,25(OH)2D3 stimulation (Seuter
et al., 2013). Moreover, the binding of VDR to its genomic loci is
a dynamic process, which takes at least some 2 h to saturate the
sites. One example is a site located 225 kb downstream of the TSS
of the chromodomain helicase DNA binding protein 7 (CHD7)
gene (Figure 2). It demonstrates that at the same locus, where
a strong ligand-dependent increase of VDR binding is observed,
the rate of open chromatin more than doubled already 40min
after incubation of THP-1 cells with 1,25(OH)2D3. At some 200
additional VDR binding loci the chromatin shows detectable but
less prominent response to 1,25(OH)2D3 treatment, while at the
remaining 500 sites the VDR ligand did not affect chromatin
accessibility. Accordingly, only at less than 20% of the latter sites
DR3-type sequences are found. At many of these sites, VDR binds
already in the absence of ligand and may have a different mode of
DNA recognition and action (see above).
In summary, at approximately a third of its genome-wide
binding loci VDR dynamically controls the epigenetic state of
chromatin. At these sites, VDR binding and chromatin opening
are tightly interconnected and provide indications for primary
1,25(OH)2D3 target genes. This allows a better understanding of
the 1,25(OH)2D3 signaling cascade.
THE USE OF ENCODE DATA FOR UNDERSTANDING
1,25(OH)2D3 SIGNALING
In addition to the above described 1,25(OH)2D3-triggered chro-
matin open, in the future there will be much more data avail-
able on the interaction of VDR and 1,25(OH)2D3 with the
epigenome. This will include FAIRE-seq and DNase-seq studies
in further 1,25(OH)2D3-responsive tissues as well as investi-
gations on changes of histone modifications and/or co-factor
binding in 1,25(OH)2D3-responsive genomic regions. However,
already at present existing genome-wide data on the annota-
tion of the genomes of human, mouse and other species can be
used. The best example is the large range of data collected by
the ENCODE consortium (ENCODE-Project-Consortium et al.,
2012). The core of the ENCODE datasets are publically avail-
able ChIP-seq results on approximately 100 transcription factors
and 20 histone modifications from more than 100 human cel-
lular systems. From the latter, the human monocytic leukemia
cell line K562 is represented with highest number of datasets,
while the majority of the other cells has not been studied with
the same intensity. At present, ENCODE data describe primarily
the basal status of cells, i.e., only in a very few cases a stimulation
with hormones, growth factor, cytokines or similar molecules
had been performed. Neither data on 1,25(OH)2D3 stimula-
tions nor VDR ChIP-seq data are comprised in the ENCODE
dataset. Nevertheless, the examples shown below will illustrate,
how already on this stage ENCODE data are useful for a more
detailed understanding of 1,25(OH)2D3 signaling.
All six VDR ChIP-seq datasets agree with observations of the
ENCODE project that (i) transcription factors bind equally likely
both up- and downstream of their target gene TSSs and (ii) the
likelihood of detecting functional transcription factor binding
sites for a given gene decreases by distance from its TSS region
(ENCODE-Project-Consortium et al., 2012). This means that, in
relation to the TSS of primary 1,25(OH)2D3 target genes, the
distribution of the VDR binding sites has a Gaussian shape. In
turn, this suggest that on the same chromosome there would
be no threshold distance for the interaction between a VDR
binding locus and the TSS of a primary 1,25(OH)2D3 target
gene. However, there are limitations provided by higher-order
structures of chromatin.
Chromatin forms loops (Kadauke and Blobel, 2009), which
contribute to many nuclear functions, such as the control of gene
expression (Misteli, 2007). Chromatin loops segregate each chro-
mosome into domains, which are separated by an insulator region
(Van Bortle and Corces, 2013). Most insulator regions are asso-
ciated with the highly conserved transcription factor CCCTC-
binding factor (CTCF) (Schmidt et al., 2012). Therefore, ChIP-
seq data for CTCF binding from multiple human cell lines, such
as provided by ENCODE (ENCODE-Project-Consortium et al.,
2012), allow a first estimation of the chromatin domain borders
(Figure 3). However, only 15–20% of all genomic CTCF binding
sites are involved in insulator function. The method chromatin
interaction analysis by paired-end tag sequencing (ChIA-PET)
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FIGURE 2 | Genomic view of 1,25(OH)2D3-dependent chromatin
opening. The IGV browser visualizes the loci of a VDR locus 225 kb
downstream of the CHD7 gene (±40 kb of the peak summit). The
peak tracks display data from THP-1 cells: a time course of
FAIRE-seq data [gray for EtOH-treated controls and turquoise for
1,25(OH)2D3 (1,25D) treatments for the indicated time periods] and a
VDR ChIP-seq data [red, from unstimulated cells and after 40min
1,25(OH)2D3 treatment]. The gene structures are shown in blue and
the sequence of the DR3-type element below the summit of the
VDR peak is indicated.
(Fullwood et al., 2009) allows an assessment of the 3-dimensional
structure of chromatin. When applied for CTCF in K562 cells it
mapped more than 120,000 intra-chromosomal, CTCF-mediated
chromatin interactions (ENCODE-Project-Consortium et al.,
2012). The high conservation of CTCF binding sites allows a reli-
able extrapolation of the CTCF ChIA-PET data from K562 cells
to THP-1 cells, for which VDR ChIP-seq data is available. The
combination of both datasets suggests that in THP-1 cells there
are some 1600 chromatin domains, which contain at least one
VDR binding site (Seuter et al., 2014). When the TSS region of
a gene is within one of these chromatin regions, it may be a
primary 1,25(OH)2D3 target. In case of the CD14 gene, CTCF
ChIA-PET data from K562 cells defined a chromatin domain
spanning from 1.5 kb upstream to 57 kb downstream of the gene’s
TSS (Figure 3). This domain spans over the whole CD14 gene
and comprises two VDR binding sites 24 and 26 kb downstream
of the gene’s TSS. This provides a straightforward gene regula-
tory scenario explaining (i) the primary response of CD14 to
1,25(OH)2D3 and (ii) why the neighboring genes of CD14 do not
respond to VDR ligand treatment.
The chromatin domain of the CD14 gene is with a size of less
than 60 kb rather small (Figure 3). In contrast, one of the largest
VDR-containing chromatin domains spans over 2.3Mb of chro-
mosome 8 and combines the MYC gene with four VDR binding
sites, of which the most prominent is 1215 kb of the gene’s TSS
(Ryynänen et al., 2013). This suggests that under the condition
of sufficiently large chromatin domains, gene regulation by VDR
can be over a distance of more than 1Mb.
At present, there is no VDR ChIA-PET data available but
will come in the future. However, via the ENCODE exper-
iment matrix (http://encodeproject.org/ENCODE/dataMatrix/
encodeDataMatrixHuman.html) there is access to ChIA-PET data
for RNA polymerase II in HeLa human cervix carcinoma and
MCF-7 human breast carcinoma and for estrogen receptor α in
MCF-7 cells. The latter may be of special interests for the breast
cancer field.
Taken together, public ENCODE data are important tools,
which can be used in combination with genome-wide data on
VDR for an extrapolation on the 3-dimensional organization of
gene regulation by 1,25(OH)2D3.
1,25(OH)2D3 TARGET GENES AS BIOMARKERS FOR THE
VITAMIN D STATUS OF HUMAN INDIVIDUALS
In contrast to a number of other nuclear receptor ligands, such as
cortisol or estrogen, the endocrinology of 1,25(OH)2D3 does not
imply any fast changes (Deluca, 2004; Norman, 2008). Under nor-
mal circumstances, either the production in UV-B exposed skin
or the intake of from diet or supplements should provide suffi-
cient amounts of vitamin D3, in order to achieve optimal serum
25(OH)D3 concentrations. The latter vitamin D metabolite is the
widely accepted indicator of the vitamin D3 status of the human
body (Hollis, 2005). The serum 25(OH)D3 concentrations change
only in the order of weeks and months, such as the result of
seasonal variations in sun exposure (Virtanen et al., 2011). This
indicates that stimulation experiments with 1,25(OH)2D3 over a
few hours, as performed in in vitro experiments, do not represent
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FIGURE 3 | Chromatin domain containing VDR binding sites. The IGV
browser was used to display the chromatin domain around the CD14 gene.
VDR ChIP-seq data from THP-1 cells [unstimulated (−) and treated for 40min
with 1,25(OH)2D3 (+), red] are shown in comparison with CTCF ChIP-seq
data from the ENCODE cell lines NHEK, HUVEC and K562 (orange) and CTCF
ChIA-PET data from K562 cells in the track view (light blue). The gene
structures are shown in blue and the sequence of the DR3-type elements
below the summits of the VDR peaks are indicated.
the physiological reality. In contrast, the effects of more long-
lasting changes of serum 25(OH)D3 concentrations should be
considered. On a genome-wide level, this was investigated first
with primary T cells isolated from nine human individuals with
variant serum 25(OH)D3 concentrations (Handel et al., 2013).
The number of the observed VDR ChIP-seq peaks, which varied
between 200 and more than 7000, correlated with the 25(OH)D3
levels of the individuals, i.e., the higher the circulating 25(OH)D3
concentrations, the more VDR loci were identified in T cells.
Unfortunately, the raw data of this study is not available, i.e., a
harmonized re-analysis in comparison with other published VDR
ChIP-seq data cannot be performed. However, from the 14,044
unique VDR peaks reported for the sum of the nine individuals,
only 442 (3.1%) associated with a DR3-type sequence (based on
HOMER score 7 settings).
Serum 25(OH)D3 concentrations vary widely from person to
person based on (i) varied diet and sun exposure, (ii) differ-
ent age and/or level of adiposity and (iii) genetic and epigenetic
variations (Engelman et al., 2008; Orton et al., 2008; Snellman
et al., 2009). The Institute of Medicine recommends a serum
25(OH)D3 level of 50 nM (Institute-of-Medicine, 2011), but it
is under debate, whether this is sufficient for every individual
(Holick, 2007). In fact, a substantial proportion of the world’s
population could be considered as vitamin D deficient. This con-
dition may accelerate age-related bone loss and morbidity from
falls and fractures. In addition, vitamin D insufficiency is asso-
ciated with a number of diseases, such as cancer, autoimmune
disorders and all components of the metabolic syndrome (more
details in the article by Bendik et al. in this issue).
This important medical problem guided to the question,
whether an insight into the genome- and transcriptome-wide
actions of VDR and 1,25(OH)2D3 can help in a more accu-
rate evaluation of the human individual’s responsiveness to, and
needs for, vitamin D. A first approach in this direction was
done by studying peripheral blood mononuclear cells (PBMCs)
and adipose tissue biopsies from 71 elderly, pre-diabetic indi-
viduals, which participated in a 5-month vitamin D3 inter-
vention trial (VitDmet) during Finnish winter (Carlberg et al.,
2013). The changes in the mRNA expression of the primary
1,25(OH)2D3 target genes CD14 and thrombomodulin (THBD),
which had been identified in a recent comparative study as
most reliable biomarkers (Standahl Olsen et al., 2013), in both
PBMCs and fat samples were correlated with the alterations in
the serum 25(OH)D3 levels of the 71 individuals. Interestingly,
only for a subset of individuals significant correlations between
the up-regulation of both genes and the intervention-induced
raise in serum 25(OH)D3 concentrations were obtained. This
suggests that, on a molecular level, not all study participants
benefited from the vitamin D3 supplementation, because (i)
they had already reached their individual optimal vitamin D
status before the start of the intervention, (ii) they carry a
genetic polymorphism making them less responsive to vita-
min D3 or (iii) other undefined reasons (Carlberg et al., 2013).
Interestingly, the categorization of the human individuals by
their vitamin D responsiveness unmasked a negative correla-
tion between changes in serum concentrations of 25(OH)D3 and
the inflammation marker interleukin 6, i.e., the more respon-
sive the study participants were to vitamin D3 supplementation,
the lower was their inflammatory status. At present, a num-
ber of other primary 1,25(OH)2D3 target genes, which were
highlighted in the comparison of VDR ChIP-seq data, are eval-
uated for their potential to serve as even better biomarkers
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for the vitamin D status of human individuals than CD14
and THBD.
In summary, vitamin D deficiency may negatively contribute
to a number of diseases. Genome-wide insight led to the use
of mRNA expression changes of the genes CD14 and THBD as
biomarkers for a molecular evaluation of vitamin D3 supple-
mentation studies. The results allow a classification of human
individuals based on their responsiveness to vitamin D3.
CONCLUSIONS
Genome-wide data on (i) the location of transcription factor
binding sites in living cells, (ii) histone modifications and (iii)
accessible chromatin, such as provided by ChIP-seq, DNase-seq
and FAIRE-seq studies, have significantly changed the view on,
and the understanding of the regulation of the entirety of the
genes of our genome. This applies also to the transcription fac-
tor VDR, for which at present ChIP-seq data from six human cell
lines and the T cells of nine human individuals are available. The
abovementioned modern genome-wide techniques allow a more
unbiased identification of transcription factor binding sites com-
pared to previous studies, which were mostly focused on regions
a few kb upstream of a primary 1,25(OH)2D3 target gene. VDR
binding loci have now been shown to be localized equally likely
up- and downstream of TSS regions in distances of even more
than 1Mb.
Genome-wide studies have confirmed DR3-type sequences as
the preferential binding sites for VDR (most likely as a het-
erodimer with RXR), but only one in seven of the close to 20,000
known VDR binding loci carry such a motif. This is unanimously
observed in all investigated cellular models. Therefore, there must
be other types of binding motifs and partnering proteins that
attract VDR to its genomic targets. These presently poorly under-
stood alternative binding modes may explain some of VDR’s
function in the (trans)repression of its target genes. Moreover,
the VDR cistrome seems to be largely cell-specific with only some
50 loci overlapping in all investigated models. However, these
conserved sites could be fundamental entry ports of VDR to
the human genome, which may serve as the unified core of the
various pleiotropic functions of 1,25(OH)2D3.
The 22,000 detected VDR binding loci within six cell lines
as well as the 14,000 peaks found in primary T cells from nine
human individuals may be far more than what is needed to
control the physiological actions of 1,25(OH)2D3, i.e., many
sites may represent rather “noise” than having a specific func-
tion. Therefore, different approaches to categorize VDR loci are
useful. It turned out that VDR binding sites that (i) carry a
DR3-type sequence, (ii) show ligand-stimulated VDR association,
(iii) co-locate with ligand-induced chromatin opening and (iv)
are conserved between several cellular systems may play a more
important role in mediating the functions of 1,25(OH)2D3 than
the vast majority of other VDR sites that lack most of these prop-
erties. Therefore, for a cellular system of interest, the combination
of (i) a genome-wide assessment of open chromatin by DNase-seq
or FAIRE-seq, (ii) the monitoring of genomic VDR loci by ChIP-
seq and (iii) a screening for DR3-type sequences below the peak
summits is an efficient tool for the prediction and identification
of primary 1,25(OH)2D3 target genes.
FUTURE PERSPECTIVES
Although historically 1,25(OH)2D3 was understood to be a hor-
mone controlling calcium homeostasis and bone formation, to
date the genome-wide the actions of VDR are best understood
and monitored in cells of the hematopoietic system. This empha-
sizes the impact of 1,25(OH)2D3 on the function of innate
and adaptive immunity. There are first indications that the core
actions of 1,25(OH)2D3 and its receptor VDR can be extrapo-
lated from hematopoietic cells to other tissues and cell types of the
human body (Carlberg et al., 2013). If this holds true, the vitamin
D status and responsiveness of a human individual can be derived
from the response of, for example, PBMCs. Technically, various
types of leukocytes can be collected far easier from blood samples
than any other tissue biopsy. Like a glucose tolerance test is used
to monitor the functionality of the carbohydrate metabolism of
an individual, there may be in the future a higher dose vitamin
D3 challenge test, where the (epi)genomic and transcriptomic
profiles of leukocytes before and after supplementation are mea-
sured. Routine measurements of healthy individuals may also in
the future more likely be based on a few selected biomarkers, such
as CD14 and THBD, while more complex scenarios in disease set-
tings, such as cancer or autoimmune diseases, will be assessed
genome- or transcriptome-wide. In the same way, basic research
on 1,25(OH)2D3 and VDRwill shift more andmore from cell cul-
ture models to primary tissues and cell types and will eventually
reach the single cell level.
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